Companies have withdrawn their interest in getting Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5 (1H,3H)-dione (TMAD) approved in the biocides Review Programme for use in slimicides (product-type 12).
Notify us until 31 January 2025 to keep this substance in the Review Programme.